Neuroendocrine tumors are a rare and diverse group of carcinoid or pancreatic tumors that secrete abnormally high quantities of hormones. Due to the absence of specific symptoms, the disease may not be diagnosed quickly. Once diagnosed however, treatment options are available.
Lanreotide is an injectable somatostatin analog that inhibits the secretion of several endocrine, exocrine and paracrine functions. It was approved for the treatment of NETs in December 2014.
In this interview, Matthew Kulke, MD, of the Dana Farber Cancer Institute provides an overview of NETs.